Updates from ICARIA-MM, A Phase 3 Study of Isatuximab Plus Pomalidomide and Low-Dose Dexamethasone Vs Pd In Relapsed and Refractory Multiple Myeloma (https://www.myeloma.org/videos/icaria-mm-isatuximab-plus-pomalidomide-low-dose-dexamethasone-vs-pd-relapsed-refractory)
Dr. Aurore Perot on the ICARIA-MM Phase III Study
Background of the study:
Isatuximab (Isa) is an approved monoclonal antibody that binds to a specific epitope on the CD38 receptor. The Phase 3 ICARIA-MM study (NCT02990338) demonstrated significantly improved progression-free survival (PFS) with Isa with pomalidomide and dexamethasone (Isa-Pd) versus pomalidomide and dexamethasone (Pd) alone (P=0.001) and a manageable safety profile.
In this video:
Dr. Aurore Perrot, CHU de Toulouse, Toulouse, France) discusses the updated results of the ICARIA-MM study.
Conclusions:
Isa-Pd demonstrates a significant improvement in time to next therapy (TTNT) and PFS2 compared with Pd. A strong trend in overall survival (OS) benefit was also seen in the Isa-Pd arm, with approximately 7 months of improvement in median OS. The overall safety profile remains unchanged from prior analyses.